Dr. Sharpless, an accomplished researcher and oncology physician, was appointed director of the cancer institute in June 2017 and quickly made modernizing research, diversifying clinical trials and improving healthcare access for the underserved key parts of his mission.
Last week, Dr. Gottlieb announced his resignation, citing a desire to spend more time with his family. Dr. Gottlieb had been commuting weekly to Washington, D.C.,from Connecticut.
HHS Secretary Alex Azar announced Dr. Sharpless’ appointment March 12 and said the search for a permanent replacement is underway.
When Dr. Sharpless arrives at the FDA, Douglas Lowy, the cancer institute’s deputy director, will serve as acting director of the NCI.
More articles on leadership:
The ambitious agenda of Allina Health COO Lisa Shannon
Hospitals in Ohio, West Virginia to lay off 70 employees
Are you effectively collaborating with the C-Suite to gain a partnership that supports your organizations goals? Here’s how to get their attention.
At Becker's 4th Annual CEO + CFO Roundtable, taking place November 2–5 in Chicago, more than 1,500 hospital and health system executives tackle decisions that determine whether organizations thrive or merely survive: protecting margins under cost pressure, choosing where to grow, renegotiating payer relationships, stabilizing the workforce and proving real ROI on technology. This is where leaders work through them together, face-to-face. Apply for complimentary registration now.